Patient receiving treatment

HDx Therapy Enabled by the Theranova Dialyser

One step closer to the natural kidney.1

One step closer to the natural kidney 1

HDx therapy enabled by the Theranova dialyser delivers superior removal of large-middle molecules compared to both conventional (high-flux) HD and HDF therapies, while maintaining stable serum albumin levels and without changing current HD machines and workflow.2,3

HDx therapy vs. high-flux HD and HDF
Patient receiving treatment
HDx therapy vs. high-flux HD and HDF

See how the Theranova dialyser works

Download the brochure and datasheet to discover how Theranova dialyser brings us a step closer to the natural kidney.1

Brochure Datasheet
A healthcare professional holds a Theranova dialyzer by a AK 98 machine
Brochure Datasheet

Choosing the Theranova dialyser may help reduce hospitalisations, medication usage and cost of care compared to high-flux HD

  • Up to 45% reduction in all-cause hospitalisations4
  • Up to 4,772 USD lower cost per patient, with savings demonstrated in 96% of the 10,000 simulations in a probability analysis of mean cost difference4
    • Randomised controlled trial of US haemodialysis patients
  • Reduced erythropoietin resistance and ESA utilisation5-8
  • Decreased dosing of supportive medications such as iron, insulin and anti-hypertensive medications6,7
    • Multi-centre, observational study; retrospective analysis; and prospective, randomised, controlled, open-label studies
Study summary: Hospitalisations and costs Study compendium: Economic outcomes

Patient-reported quality of life may improve using the Theranova dialyser compared to high-flux HD

  • Improved effects and burden of kidney disease9
    • Prospective, multi-centre, observational study
  • Improved sleep quality, energy level, and general well-being10
    • Single-centre, unblinded, exploratory pilot study
Study summary: Burden of kidney disease Study summary: Well-being, energy and sleep

Additional studies detailing positive patient outcomes

Up to 2.5 hours reduction in patient-reported dialysis recovery time11

Single-centre, retrospective analysis

Study summary: Dialysis recovery time

Reduction in patient-reported pruritus12

Randomised, prospective, controlled, open-label study

Study summary: Pruritus

Up to 55% reduction in patients meeting diagnostic criteria for restless leg syndrome (RLS)9

Prospective, multi-centre, observational study

Study summary: RLS

Learn more

See how Vantive’s Theranova dialyser enables HDx therapy, delivering expanded haemodialysis.

Theranova dialysers for HDx therapy

Vantive, HDx, MCO and Theranova are trademarks of Vantive Health LLC or its affiliates.

References

  1. Zweigart C, Boschetti-de-Fierro A, Hulko M, et al. Medium cut-off membranes — closer to the natural kidney removal function. Int J Artif Organs. 2017; 40(7):328-334.

  2. Theranova Instructions for Use, 2021.

  3. Kirsch AH, Lyko R, Nilsson LG, et al. Performance of hemodialysis with novel medium cut-off dialyzers [published correction appears in Nephrol Dial Transplant. 2021 Jul 23;36(8):1555-1556]. Nephrol Dial Transplant. 2017;32(1):165-172.

  4. Blackowicz MJ, Falzon L, Beck W, Tran H, Weiner DE. Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States. Hemodial Int. 2022;26:449-455.

  5. Hadad-Arrascue F, Nilsson LG, Rivera AS, Bernardo AA, Cabezuelo Romero JB. Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial. Ther Apher Dial. 2022;26(1):37-44.

  6. Ariza JG, Walton SM, Suarez AM, Sanabria M, Vesga JI. An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia. Ther Apher Dial. 2021;25(5):621-627.

  7. Sanabria RM, Hutchison CA, Vesga, JI, Ariza JG, Sanchez R, Suarez AM. Expanded hemodialysis and its effects on hospitalizations and medication usage: A  cohort study. Nephron. 2021;145(2):179-187.

  8. Lim JH, Jeon Y, Yook JM, et al. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial. Sci Rep. 2020;10(1):1-10.

  9. Alarcon JC, Bunch A, Ardila F, et al. Impact of medium cut-off dialyzers on patient-reported outcomes: COREXH Registry. Blood Purif. 2021;50(1):110–118.

  10. Penny JD, Jarosz P, Salerno FR, Lemoine S, McIntyre CW. Impact of expanded hemodialysis using medium cut-off dialyzer on quality of life: Application of dynamic patient-reported outcome measurement tool. Kidney Med. 2021;3(6):992-1002.e1. 

  11. Bolton S, Gair R, Nilsson LG, Matthews M, Stewart L, McCullagh N. Clinical assessment of dialysis recovery time and symptom burden: Impact of switching hemodialysis therapy mode. Patient Relat Outcome Meas. 2021;12:315-321.

  12. Lim JH, Park Y, Yook JM, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients. Sci Rep. 2020;10(1):1-11.